Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

G G Chabot(Centre National de la Recherche Scientifique), D Abigerges, G. Catimel, Stéphane Culine, M Forni, Jean Marc Extra, M. Mahjoubi, Patrice Herait, Jean‐Pierre Armand, R. Bugat, M. Clavel, M.E. Marty

Annals of Oncology

February 1, 1995

10.1093/oxfordjournals.annonc.a059109

Cited by 173

Abstract

Related Papers

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Y H Hsiang, Robert Hertzberg, Sidney M. Hecht et al.|Journal of Biological Chemistry|1985|2.3k

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

Yasuyoshi Kawato, Masashi Aonuma, Yasuhide Hirota et al.|PubMed|1991|874

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.

E Gupta, Timothy M. Lestingi, Rosemarie Mick et al.|PubMed|1994|506

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

N Masuda, M. Fukuoka, Y Kusunoki et al.|Journal of Clinical Oncology|1992|452

Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.

Takehiko Kunimoto, Kazuo Nitta, Takashi Tanaka et al.|PubMed|1987|412